Sixty-two Cases of Intractable Ascites due to Cirrhosis Treated by the Modified Wulingsan Power plus Abdominal Reinfusion of the Concentrated Ascites after Ultrafiltration

Objective： To observe the clinical therapeutic effects of Wulingsan Jiawei （五苓散加味 Supplemented Powder of Five Drugs with Poria, SPFDP） plus abdominal reinfusion of concentrated ascites after ultrafiltration （ARCAU） for intractable ascites due to cirrhosis （IAC）. Methods： 124 cases of IAC were random...

Full description

Saved in:
Bibliographic Details
Published in:Journal of traditional Chinese medicine 2009-06, Vol.29 (2), p.115-120
Main Author: 赵和平 张自然 丁保华 郭世民 赵耀州 董淑娜
Format: Article
Language:English
Subjects:
Adult
ALT活性
Ascites - drug therapy
Ascites - therapy
Female
Humans
Male
Plant Extracts - therapeutic use
Treatment Outcome
Ultrafiltration - methods
上腹部
治疗组
腹水浓缩
腹水超滤
醛固酮水平
顽固性肝硬化腹水
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective： To observe the clinical therapeutic effects of Wulingsan Jiawei （五苓散加味 Supplemented Powder of Five Drugs with Poria, SPFDP） plus abdominal reinfusion of concentrated ascites after ultrafiltration （ARCAU） for intractable ascites due to cirrhosis （IAC）. Methods： 124 cases of IAC were randomly divided into two groups, a treatment group of 62 cases treated by oral administration of SPFDP plus ARCAU and a control group of 62 cases treated simply by ARCAU. Aldosterone （ALD） level in plasma, levels of total bilirubin （TBIL） and albumin （ALB） in serum, and activity of alanine aminotransferase （ALT） were determined in the two groups before and after treatment. Results： After treatment ALT activity and TBIL level in the treatment group were significantly lower than those in the control group, and ALB content in the treatment group was significantly higher than that in the control group. ALD level of the treatment group significantly decreased after treatment as compared with that before treatment, while that of the control group did not decreased significantly after treatment. The treatment group was significantly superior in keeping down ascites to the control group. Conclusion： SPFDP plus ARCAU treatment oflAC can markedly raise the clinical therapeutic effect, reduce recurrence of ascites, and improve the liver function, which can produce a significant decrease in ALD level in plasma and a marked increase in ALB content.
ISSN:0255-2922
DOI:10.1016/S0254-6272(09)60046-7